MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 16.05.2026
Trean Insurance Group Operativer Cashflow 2011-2026 | TIG
Operativer Cashflow Jährlich Trean Insurance Group
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 109 M | 94.4 M | 50 M | 52.2 M | 75.3 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 109 M | 50 M | 76.2 M |
Operativer Cashflow Vierteljährlich Trean Insurance Group
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 76.5 M | 40.1 M | 8.75 M | - | 53.4 M | 22.8 M | -2.96 M | - | 32.2 M | 31.8 M | 7.43 M | - | 32.1 M | 14.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 76.5 M | -2.96 M | 28.8 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.69 | 2.74 % | $ 198 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 31.72 | 2.82 % | $ 2.11 B | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
456 M | $ 93.62 | 1.49 % | $ 22.6 B | Germany |
 |
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 53.82 | 4.33 % | $ 4.84 B |  Schweiz |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 2.76 | 3.96 % | $ 258 M | Israel |
 |
Abcam plc
ABCM
|
28.7 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
-10.4 M | $ 0.75 | 9.65 % | $ 34.3 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
10.5 M | $ 31.98 | 2.21 % | $ 861 M | USA |
 |
Affimed N.V.
AFMD
|
-110 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 21.97 | 0.14 % | $ 284 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
-23.9 M | $ 2.72 | -2.69 % | $ 174 M | USA |
 |
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
902 M | $ 8.02 | 0.06 % | $ 5.45 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
-64.7 M | $ 11.78 | 0.26 % | $ 10.1 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-4.77 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-78.2 M | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
-27.6 M | $ 0.9 | 1.45 % | $ 150 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-483 M | - | - | $ 3.37 B | China |
 |
ImmuCell Corporation
ICCC
|
2.48 M | $ 10.62 | 1.1 % | $ 95.9 M | USA |
 |
Anika Therapeutics
ANIK
|
11.2 M | $ 14.67 | -1.48 % | $ 210 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.35 | -2.62 % | $ 5.51 M | Israel |